biostudies-literatureAbe KNational Institute of Allergy and Infectious DiseasesNCATS NIH HHSNIDA NIH HHSNIAID NIH HHSNIH HHSNational Science Foundation3310-3320https://www.ebi.ac.uk/biostudies/studies/S-EPMC12726064biostudies-literatureUnknown214(12)The National Institutes of Health-funded IMPACC (IMmunoPhenotyping Assessment in a COVID-19 Cohort) evaluated longitudinal clinical and immunological features of human patients hospitalized for COVID-19. This study focuses on comparing the novel NULISAseq assay with the Olink platform using a subset of participants to assess their efficacy in predicting COVID-19 severity and understanding immune response dynamics. Our findings reveal that NULISAseq could provide superior detectability and dynamic range across various targets. Elastic net analysis demonstrated that specific proteins, including amphiregulin, effectively predict COVID-19 severity from sera at admission (samples drawn within 96 h of admission), with a test area under the curve of 0.84. Longitudinal analysis identified significJournal of immunology (Baltimore, Md. : 1950)Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.PMC12726064R01AI145835-01A1S1R01 AI104870UM1 TR0045283U01AI167892-01S2U19 AI0626294U19AI090023-11U54 AI1427663U01AI167892-03S2U19 AI1186105U19AI062629-175U19AI118608-043U19AI089992-09R01 AI122220U19 AI128910U19 AI1289135R01AI104870-074U19AI118610-065T32DA018926-185U19AI125357-05R01 AI1358033U19AI077439-133U19AI128913-035U54AI142766-035U19AI128913-03T32 DA018926U19 AI090023U01 AI1678925U19AI057229-175U19AI057229-18DMS2310836R01AI1222205U19AI128910-04U19 AI0774395R01AI135803-03U19 AI118608R01 AI145835U19 AI125357U19 AI057229UM1TR004528U19AI128913-04S13U19AI1289130U19 AI089992Peters BHafler DASimon VKheradmand FAgudelo Higuita NICalfee CSSchaenman JAugustine ADNguyen TTRouphael NErle DJKleinstein SHMaecker HTMcComsey GASekaly RPCorry DBDavis MMReed EFMetcalf JPShaw ACEhrlich LIRMesser WBHaddad EKDiray-Arce JOzonoff AMelamed ECairns CBKim-Schulze SBaden LRBrakenridge SCPulendran BAbe KHough CLNadeau KCMontgomery RRKraft MHolmes THAtkinson MABime CFernandez-Sesma ABecker PMLevy OIMPACC NetworkfalseEvaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.The National Institutes of Health-funded IMPACC (IMmunoPhenotyping Assessment in a COVID-19 Cohort) evaluated longitudinal clinical and immunological features of human patients hospitalized for COVID-19. This study focuses on comparing the novel NULISAseq assay with the Olink platform using a subset of participants to assess their efficacy in predicting COVID-19 severity and understanding immune response dynamics. Our findings reveal that NULISAseq could provide superior detectability and dynamic range across various targets. Elastic net analysis demonstrated that specific proteins, including amphiregulin, effectively predict COVID-19 severity from sera at admission (samples drawn within 96 h of admission), with a test area under the curve of 0.84. Longitudinal analysis identified signific2025-01-01T00:00:00Z2025 Dec2026-06-06T09:51:07.181Z2026-05-28T03:12:47.853ZS-EPMC127260644116671910.1093/jimmun/vkaf263